2-Ethyl-butyric acid hydrazide | 88141-09-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Ethyl-butyric acid hydrazide
• 英文别名: 2-Ethylbutanehydrazide
• CAS: 88141-09-7
• 化学式: C₆H₁₄N₂O
• mdl: MFCD03422931
• 分子量: 130.19
• InChiKey: ITUUDQHMMMKCCX-UHFFFAOYSA-N

物化性质

• 沸点：
  264.7±9.0 °C(Predicted)
• 密度：
  0.946±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Ethyl-butyric acid hydrazide 在 盐酸 、 sodium carbonate 、 溶剂黄146 作用下， 以 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 32.0h， 生成 (5R,6S)-6-Acetylamino-5-amino-1-(2-ethyl-butyryl)-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors

  摘要：

  1,4,5,6-Tetrahydropyridazine derivative 15 and its C-5 epimer 19, which possessed side chains similar to GS4071, were synthesized via a hetero Diels-Alder reaction, and evaluated as influenza neuraminidase inhibitors. Compounds 15 and 19 exhibited a microM range of influenza neuraminidase inhibitory activity.

  DOI：

  10.1016/s0960-894x(99)00280-2
• 作为产物：
  描述：

  2-乙基丁酸乙酯 在 一水合肼 作用下， 以 甲醇 为溶剂， 以19%的产率得到2-Ethyl-butyric acid hydrazide
  参考文献：
  名称：

  [EN] AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS
  [FR] DÉRIVÉS D'AZOLE EN TANT QU'INHIBITEURS DE LA VOIE WNT

  摘要：

  本发明涉及公式I的新化合物，涉及其制备过程，含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受到Wnt信号通路过度激活影响的疾病或病症中发挥特定作用。例如，它们可用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症。

  公开号：

  WO2010139966A1

文献信息

• Azole Derivatives as WTN Pathway Inhibitors
  申请人：Holsworth Daniel

  公开号：US20120208828A1

  公开（公告）日：2012-08-16

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，其制备过程，含有这些化合物的制药配方以及它们在治疗中的应用。这些化合物在防治或治疗Wnt通路信号过度激活引起的疾病或症状方面具有特殊用途。例如，它们可以用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症的治疗。
• Biarylpyrazolyl Oxadiazole as Potent, Selective, Orally Bioavailable Cannabinoid-1 Receptor Antagonists for the Treatment of Obesity
  作者：Suk Ho Lee、Hee Jeong Seo、Sung-Han Lee、Myung Eun Jung、Ji-Hyun Park、Hyun-Ju Park、Jakyung Yoo、Hoseop Yun、Jooran Na、Suk Youn Kang、Kwang-Seop Song、Min-ah Kim、Chong-Hwan Chang、Jeongmin Kim、Jinhwa Lee

  DOI：10.1021/jm800843r

  日期：2008.11.27

  Since the CB1 cannabinoid receptor antagonist 1 (SR141716, rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In the present study, biarylpyrazole analogues based on a pyrazole core coupled with 1,3,4-oxadiazole were synthesized and tested for CB1 receptor binding affinity. Thorough SAR studies to optimize pyrazole substituents as well as 1,3,4-oxadiazole ring led to several novel CB1 antagonists with IC50 similar to 1 nM for the CB1 receptor binding. Among these analogues, we identified 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl)-5-(1-(trifluoromethyl)cyclopropyl)-1,3,4-oxa- diazole 43c as a promising precandidate for the development as an antiobesity agent.
• Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists
  作者：Jong Yup Kim、Hee Jeong Seo、Sung-Han Lee、Myung Eun Jung、Kwangwoo Ahn、Jeongmin Kim、Jinhwa Lee

  DOI：10.1016/j.bmcl.2008.10.130

  日期：2009.1

  Since the CB1 receptor antagonist SR141716 (rimonabant) was reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target in the treatment of obesity. Several series of derivatives based on diarylimidazolyl oxadiazole and thiadiazole scaffolds were synthesized and tested for CB1 receptor binding affinity. SAR studies directed toward the optimization of imidazole scaffolds resulted in the discovery of 10s which showed highest potency for CB1 receptor binding affinity (IC50 = 1.91 nM) prepared to date. (C) 2008 Elsevier Ltd. All rights reserved.
• EMILSSON, H.;LEWISSON, A.;SELANDER, H., ACTA PHARM. SUEC., 1983, 20, N 3, 161-180
  作者：EMILSSON, H.、LEWISSON, A.、SELANDER, H.

  DOI：——

  日期：——
• US8883827B2
  申请人：——

  公开号：US8883827B2

  公开（公告）日：2014-11-11